Atisama Therapeutics

Atisama Therapeutics is a clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapies for inflammatory disease.

Founded on the principle of restoring molecular balance for lasting health, the Company’s SSO platform is producing drug candidates that down-regulate disease-driving isoforms and upregulates their protective counterparts; a dual-action mechanism unique to the SSO modality.

Atisama’s lead asset, RB042, is an inhaled SSO currently in Phase One clinical development.

Atisama has several other programmes leveraging the novel SSO platform.

Year established:  2020
Lead Researcher & Founder: Merlin Thomas,
Co-founders: Steve Wilton, Kevin Pfleger
Website: atisama.com